NCT00365027

Brief Summary

It has been suggested that in IVF cycles where GNRH agonist is utilized for final oocyte maturation in patients at risk of ovarian hyperstimulation, pregnancy rates are reduced. We hypothesize that the use of GNRH antagonist reduces pregnancy rates through an effect on the endometrium and not oocyte quality, therefore better results may be obtained by not returning these embryos in a fresh cycle but rather cryopreserving them and returning them to the uterus and a later stage.

Trial Health

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 15, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 16, 2006

Completed
Last Updated

September 4, 2015

Status Verified

September 1, 2015

First QC Date

August 15, 2006

Last Update Submit

September 3, 2015

Conditions

Ovarian Hyperstimulation SyndromeInfertility DrugsFemale

Keywords

GNRH agonistovarian hyperstimulation syndromeEmbryo cryopreservation

Outcome Measures

Primary Outcomes (4)

  • Implantation rate per transfer

  • Pregnancy rate per embryo transfer

  • Implantation rate per IVF cycle

  • Pregnancy rate per IVF cycle

Interventions

Delayed embryo transferPROCEDURE

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Woman at risk of ovarian hyperstimulation syndrome in IVF cycles for whom GNRH agonist was utilized for final oocyte maturation

You may not qualify if:

  • Patient's refusal to participate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Ovarian Hyperstimulation Syndrome

Condition Hierarchy (Ancestors)

Ovarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesGonadal DisordersEndocrine System Diseases

Study Officials

  • Eliezer Shalev

    HaE'mek medical center

    STUDY CHAIR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

August 15, 2006

First Posted

August 16, 2006

Last Updated

September 4, 2015

Record last verified: 2015-09